{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Fouladi M"],"funding":["NCI NIH HHS"],"pagination":["3529-34"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3179253"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["29(26)"],"pubmed_abstract":["<h4>Purpose</h4>To estimate the maximum-tolerated dose (MTD), describe dose-limiting toxicities (DLTs), and characterize pharmacokinetic properties of MK-0752, a gamma secretase inhibitor, in children with refractory or recurrent CNS malignancies.<h4>Patients and methods</h4>MK-0752 was administered once daily for 3 consecutive days of every 7 days at escalating dosages starting at 200 mg/m(2). The modified continual reassessment method was used to estimate the MTD. A course was 28 days in duration. Pharmacokinetic analysis was performed during the first course. Expression of NOTCH and hairy enhancer of split (HES) proteins was assessed in peripheral-blood mononuclear cells (PBMCs) before and following treatment with MK-0752.<h4>Results</h4>Twenty-three eligible patients were enrolled: 10 "],"journal":["Journal of clinical oncology : official journal of the American Society of Clinical Oncology"],"pubmed_title":["Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study."],"pmcid":["PMC3179253"],"funding_grant_id":["U01 CA081457","U01 CA81457"],"pubmed_authors":["Boyett JM","Packer RJ","Gilbertson RJ","Onar-Thomas A","Kocak M","Kun LE","Wagner LM","Gururangan S","Fouladi M","Gajjar A","Stewart CF","Goldman S","Demuth T","Olson J"],"additional_accession":[]},"is_claimable":false,"name":"Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study.","description":"<h4>Purpose</h4>To estimate the maximum-tolerated dose (MTD), describe dose-limiting toxicities (DLTs), and characterize pharmacokinetic properties of MK-0752, a gamma secretase inhibitor, in children with refractory or recurrent CNS malignancies.<h4>Patients and methods</h4>MK-0752 was administered once daily for 3 consecutive days of every 7 days at escalating dosages starting at 200 mg/m(2). The modified continual reassessment method was used to estimate the MTD. A course was 28 days in duration. Pharmacokinetic analysis was performed during the first course. Expression of NOTCH and hairy enhancer of split (HES) proteins was assessed in peripheral-blood mononuclear cells (PBMCs) before and following treatment with MK-0752.<h4>Results</h4>Twenty-three eligible patients were enrolled: 10 ","dates":{"release":"2011-01-01T00:00:00Z","publication":"2011 Sep","modification":"2025-04-26T03:16:55.316Z","creation":"2019-03-26T23:49:33Z"},"accession":"S-EPMC3179253","cross_references":{"pubmed":["21825264"],"doi":["10.1200/jco.2011.35.7806","10.1200/JCO.2011.35.7806"]}}